Development and application of statistical models for medical scientific researchAnalysis and support of clinical decision makin
Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: Worldwide, over 10 million people are killed or hospitalized because of traumatic brain ...
BACKGROUND: Traumatic brain injury (TBI) is a leading cause of death and disability. In many cases o...
BACKGROUND: Traumatic brain injury (TBI) is a leading cause of death and disability. In many cases o...
ObjectiveThe antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit in traum...
Background: Worldwide, traumatic brain injury (TBI) kills or hospitalises over 10 million people eac...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
Background: Worldwide, traumatic brain injury (TBI) kills or hospitalises over 10 million people eac...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BackgroundAnti-fibrinolytic medications decrease traumatic intracranial haemorrhage (ICH). Tranexami...
OBJECTIVE: To assess the effect of tranexamic acid (which reduces bleeding in surgical patients and ...
Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: Worldwide, over 10 million people are killed or hospitalized because of traumatic brain ...
BACKGROUND: Traumatic brain injury (TBI) is a leading cause of death and disability. In many cases o...
BACKGROUND: Traumatic brain injury (TBI) is a leading cause of death and disability. In many cases o...
ObjectiveThe antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit in traum...
Background: Worldwide, traumatic brain injury (TBI) kills or hospitalises over 10 million people eac...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
Background: Worldwide, traumatic brain injury (TBI) kills or hospitalises over 10 million people eac...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BackgroundAnti-fibrinolytic medications decrease traumatic intracranial haemorrhage (ICH). Tranexami...
OBJECTIVE: To assess the effect of tranexamic acid (which reduces bleeding in surgical patients and ...
Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce ...
BACKGROUND: Worldwide, over 10 million people are killed or hospitalized because of traumatic brain ...